Roger Inhorn

863 total citations
9 papers, 215 citations indexed

About

Roger Inhorn is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Roger Inhorn has authored 9 papers receiving a total of 215 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Cancer Research and 2 papers in Molecular Biology. Recurrent topics in Roger Inhorn's work include Cancer Treatment and Pharmacology (3 papers), Breast Cancer Treatment Studies (2 papers) and HER2/EGFR in Cancer Research (2 papers). Roger Inhorn is often cited by papers focused on Cancer Treatment and Pharmacology (3 papers), Breast Cancer Treatment Studies (2 papers) and HER2/EGFR in Cancer Research (2 papers). Roger Inhorn collaborates with scholars based in United States and France. Roger Inhorn's co-authors include Alan D. D’Andrea, James N. Ihle, Noriko Sato, Zhu Yuan, Matthias Eder, Atsushi Miyajima, Bernard Mathey-Prévôt, Miklos Pless, Bruce A. Witthuhn and Frederick W. Quelle and has published in prestigious journals such as Molecular and Cellular Biology, Biochemical and Biophysical Research Communications and Breast Cancer Research and Treatment.

In The Last Decade

Roger Inhorn

9 papers receiving 210 citations

Peers

Roger Inhorn

ONCOL

IMMUN

HEMAT

Carliann M. Costanzo United States

Yee Peng Phoon United States

Daniel Dávila‐González United States

Robert J. Van Gulick United States

Joanna Phillips United States

Gabriel Champenois France

Kendra R. Cook United States

Catherine A. Eberlein United Kingdom

Betelehem W. Yacob United States

Ella Levit‐Zerdoun Germany

Carliann M. Costanzo United States

Roger Inhorn

189 ×1.5

ONCOL

170 ×2.2

113 ×1.6

IMMUN

59 ×1.1

20 ×1.3

HEMAT

Citations per year, relative to Roger Inhorn Roger Inhorn (= 1×) peers Carliann M. Costanzo

Countries citing papers authored by Roger Inhorn

Since Specialization

Citations

This map shows the geographic impact of Roger Inhorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Inhorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Inhorn more than expected).

Fields of papers citing papers by Roger Inhorn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Inhorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Inhorn. The network helps show where Roger Inhorn may publish in the future.

Co-authorship network of co-authors of Roger Inhorn

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Inhorn. A scholar is included among the top collaborators of Roger Inhorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Inhorn. Roger Inhorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Anderson, Eric, F. Lee Lucas, Michael J. Hall, et al.. (2024). Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI). npj Precision Oncology. 8(1). 67–67. 3 indexed citations

Rueter, Jens, Eric Anderson, Leah Graham, et al.. (2023). The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State. JCO Precision Oncology. 7(7). e2200619–e2200619. 4 indexed citations

Yardley, Denise A., et al.. (2016). Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial. Clinical Breast Cancer. 16(3). 180–187. 11 indexed citations

Yardley, Denise A., Brooke Daniel, Roger Inhorn, et al.. (2010). A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With Locally Advanced Breast Cancer. Clinical Breast Cancer. 10(5). 367–372. 17 indexed citations

Spigel, David R., F. Anthony Greco, Dana S. Thompson, et al.. (2010). Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 11(3). 198–203. 10 indexed citations

Yardley, Denise A., Howard A. Burris, N. W. Peacock, et al.. (2010). A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Research and Treatment. 123(2). 471–475. 21 indexed citations

Yuan, Zhu, Miklos Pless, Roger Inhorn, Bernard Mathey-Prévôt, & Alan D. D’Andrea. (1996). The Murine DUB-1 Gene Is Specifically Induced by the βc Subunit of the Interleukin-3 Receptor. Molecular and Cellular Biology. 16(9). 4808–4817. 48 indexed citations

Quelle, Frederick W., Noriko Sato, Bruce A. Witthuhn, et al.. (1994). JAK2 Associates with the β _c Chain of the Receptor for Granulocyte-Macrophage Colony-Stimulating Factor, and Its Activation Requires the Membrane-Proximal Region. Molecular and Cellular Biology. 14(7). 4335–4341. 83 indexed citations

Inhorn, Roger & Douglas M. Tollefsen. (1986). Isolation and characterization of a partial cDNA clone for heparin cofactor II. Biochemical and Biophysical Research Communications. 137(1). 431–436. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact